Boiron CEO cites difficult years following homeopathy delisting
Boiron CEO stated the group has faced lean years since homeopathy delisting in France.
Published 19sem·1 sourceNotable
The fact
This delisting severely impacted revenues of the French laboratory specialized in homeopathic products.
Boiron must reinvent itself commercially faced with drastically reduced reimbursed sales channels.
🔗Click the link to read an article on the topic:
What if you saw the whole news differently?Factae cross-checks hundreds of sources worldwide to keep only the fact, no opinion. Explore the front page.→Observed impact
Impact récessif sur les ventes de Boiron depuis le déremboursement de l'homéopathie
Restructuration commerciale du laboratoire pour diversifier ses sources de revenus
France · © OpenStreetMap, OpenMapTiles, OpenFreeMapWorld map →Auto-synthesis from 1 media source · identified on April 27, 2026